



## **Somaxon Pharmaceuticals to Present at JP Morgan 26th Annual Healthcare Conference**

**SAN DIEGO, CA - January 3, 2008** - Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that David Hale, executive chairman and interim chief executive officer, will present a company update at the JPMorgan 26th Annual Healthcare Conference at The Westin St. Francis, San Francisco, on Thursday, January 10, 2008, at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

A live webcast of the presentation will be available in the Investor Relations section of the company's website under Event Scheduler at [www.somaxon.com](http://www.somaxon.com). The webcast will be archived and accessible for at least 14 days.

### **About Somaxon Pharmaceuticals**

Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin HCl) for the treatment of insomnia. The company has completed a pilot Phase 2 trial for nalmefene in smoking cessation with positive results. It has also completed a Phase 2/3 clinical trial for nalmefene for the treatment of pathological gambling that did not achieve statistical significance for the primary or secondary endpoints. The company is evaluating the results from both of these trials before making determinations regarding the future of the nalmefene program.

For more information, please visit the company's web site at [www.somaxon.com](http://www.somaxon.com).

### **Contacts:**

Meg McGilley  
Chief Financial Officer  
(858) 480-0402

Rob Whetstone  
PondelWilkinson Inc.  
(310) 279-5963